scholarly journals Endoscopic Surgery for Delayed Wound Healing After Achilles Tendon Suture Repair: A Report of Three Cases

2021 ◽  
Author(s):  
Yu‐ping Yang ◽  
Hong‐yu Chen ◽  
Guo‐qing Cui ◽  
Xiao‐lei Xiu ◽  
Xiao‐peng Liu ◽  
...  
Keyword(s):  
Wound Healing ◽  
Achilles Tendon ◽  
Endoscopic Surgery ◽  
Suture Repair ◽  
Delayed Wound Healing ◽  
Tendon Suture

Deficiencies in micronutrients are common in Trauma patients but not related with delayed wound healing

2009 ◽  
Vol 34 (03) ◽  
Author(s):  
SC Blass ◽  
C Reimann ◽  
S Ellinger ◽  
H Goost ◽  
C Burger ◽  
...  
Keyword(s):  
Wound Healing ◽  
Trauma Patients ◽  
Delayed Wound Healing

Pengaruh Luka Iris Pada Tikus Dengan Paparan Hidrogen Peroxida 3% terhadap Epitelisasi dan Pembentukan Eksudat pada Permukaan Epitel Kulit.

2020 ◽  
Vol 17 (2) ◽  
pp. 172
Author(s):  
HARMAN AGUSAPUTRA ◽  
MARIA SUGENG ◽  
AYLY SOEKAMTO ◽  
ATIK WULANDARI
Keyword(s):  
Hydrogen Peroxide ◽  
Wound Healing ◽  
The Other ◽  
Delayed Wound Healing ◽  
Peroxide Group ◽  
Hemostatic Effect ◽  
Significant Difference ◽  
Negative Effect ◽  
Wound Healing Effect ◽  
Epithelial Growth

<p><strong>Abstract</strong></p><p><strong>Background:</strong> Hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) as antiseptic has been used frequently to clean woundsin in hospitals and clinics. Hydrogen peroxide has the effectof strong oxidative that can kill pathogens. It can clean up debris and necrotic tissuesin wounds. Hydrogen peroxidealso has hemostatic effect that can help to stop bleeding. Besides antiseptic effects, hydrogen peroxide i s suspected of having negative effect in wound healing. Hydrogen peroxide presumably could cause delayed wound healing by exudate formation and delayed epithelial growth.</p><p><strong>Method</strong>: This study was conducted in the laboratory using 48 white mice that were divided into 2 groups. All the mice were purposely wounded. Afterwards in one group the wounds were clean up using hydrogen peroxide, while in the other group without hydrogen peroxide as control. The wounds of both groups were observed on day 1, day 3 and day 7. On day 1 and day 3, both groups did not show significant difference.</p><p><strong>R</strong><strong>esult</strong> : on day 7 showed that the wound healing in hydrogen peroxide group were delayed. Fifty percent of them had the formation of exudate and 62.5% of them showed delayed epithelial growth.</p><p><strong>Conclusion </strong>: This study could show hydrogen peroxide as wound antiseptic has delayed wound healing effect.</p><p><strong>Keyword</strong>: hydrogen peroxide, wound healing</p>

Cutaneous wound healing is impaired in hemophilia B

Blood ◽  
2006 ◽  
Vol 108 (9) ◽  
pp. 3053-3060 ◽  
Author(s):  
Maureane Hoffman ◽  
Anna Harger ◽  
Angela Lenkowski ◽  
Ulla Hedner ◽  
Harold R. Roberts ◽  
...  
Keyword(s):  
Wound Healing ◽  
Time Course ◽  
Ferric Iron ◽  
Hemophilia B ◽  
Cutaneous Wound Healing ◽  
Delayed Wound Healing ◽  
Cutaneous Wound ◽  
Time Points ◽  
Hemophilic Arthropathy ◽  
Healing Wounds

Abstract We used a mouse model to test the hypothesis that the time course and histology of wound healing is altered in hemophilia B. Punch biopsies (3 mm) were placed in the skin of normal mice and mice with hemophilia. The size of the wounds was measured daily until the epidermal defect closed. All wounds closed in mice with hemophilia by 12 days, compared with 10 days in normal animals. Skin from the area of the wound was harvested at different time points and examined histologically. Hemophilic animals developed subcutaneous hematomas; normal animals did not. Macrophage infiltration was significantly delayed in hemophilia B. Unexpectedly, hemophilic mice developed twice as many blood vessels in the healing wounds as controls, and the increased vascularity persisted for at least 2 weeks. The deposition and persistence of ferric iron was also greater in hemophilic mice. We hypothesize that iron plays a role in promoting excess angiogenesis after wounding as it had been proposed to do in hemophilic arthropathy. We have demonstrated that impaired coagulation leads to delayed wound healing with abnormal histology. Our findings have significant implications for treatment of patients with hemophilia, and also highlight the importance of rapidly establishing hemostasis following trauma or surgery.

scholarly journals SAT0047 RISK FACTORS FOR THE POSTOPERATIVE DELAYED WOUND HEALING IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH A BIOLOGICAL AGENT

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 954.3-954
Author(s):  
S. Okita ◽  
H. Ishikawa ◽  
A. Abe ◽  
S. Ito ◽  
A. Murasawa ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Risk Factors ◽  
Wound Healing ◽  
Retrospective Study ◽  
Nutritional Status ◽  
Disease Activity ◽  
Disease Duration ◽  
Foot And Ankle ◽  
Delayed Wound Healing ◽  
Chugai Pharmaceutical

Background:It has been suggested that perioperative use of biological disease-modifying anti-rheumatic drugs (bDMARDs) in rheumatoid arthritis (RA) patients carries risks for the surgical-site infection and the delayed wound healing (DWH); however, the risk of DWH with perioperative use of bDMARDs has not reached a general consensus.Objectives:This retrospective study aimed to investigate the risk factors associated with DWH after orthopedic surgery in RA patients treated with bDMARDs.Methods:We reviewed medical records of 277 orthopedic procedures for 188 RA patients treated with bDMARDs between from 2014 to 2017 in Niigata Rheumatic Center. As preoperative nutritional status assessment, we evaluated body mass index (BMI), prognostic nutritional index (PNI), and CONtrolling NUTritional status (CONUT). In addition, we evaluated DAS28-CRP, DAS28-ESR, face scale for pain, global health (GH), and Health Assessment Questionnaire-Disability Index (HAQ-DI) to assess the disease activity. Univariate and multivariate logistic regression analyses were performed to evaluate the risk factor for DWH.Results:The major characteristics of the patients in 277 procedures were mean age of 63.2 years old and mean disease duration of 18.2 years. Surgical site were hand and wrist (145 procedures), foot and ankle (76), hip and knee (31), elbow and shoulder (24), and spine (1). Seventy-four patients were treated with tocilizumab, 62 with etanercept, 55 with golimumab, 49 with abatacept, 16 with infliximab, 15 with adalimumab, and 6 with certolizumab. According to nutritional assessment in PNI and CONUT, 63% (n=175) and 47% (n=130) were normal nourished patients, respectively.In 277 procedures, DWH were identified in 24 patients (8.6%). The following variables were significant in the univariate analyses: disease duration (OR 1.053; 95% CI 1.010–1.099; p=0.016), foot and ankle surgery (OR 7.091; 95% CI 2.130–23.603; p=0.001), tocilizumab (OR 0.286; 95% CI 0.093–0.881; p=0.029) (Table 1). These variables were entered into a multivariate model, and it was revealed that pre-operative use of tocilizumab (OR 0.265; 95% CI 0.074–0.953; p=0.042) and procedures in the foot and ankle (OR 6.915; 95% CI 1.914–24.976; p=0.003) were associated with an increased risk of DWH (Table 1).Conclusion:As previous study on tocilizumab described, the current retrospective study suggested that pre-operative use of tocilizumab and procedures in the foot and ankle were risk factors for DWH. Pre-operative disease activity and nutritional status were not independent risk factors for an increase in the prevalence of DWH.References:[1] Momohara S, Hashimoto J, Tsuboi H et al. Analysis of perioperative clinical features and complications after orthopaedic surgery in rheumatoid arthritis patients treated with tocilizumab in a real-world setting: Results from the multicentre tocilizumab in perioperative period (TOPP) study. Modern rheumatology. 2013, 23: 440-9.Disclosure of Interests:Shunji Okita: None declared, Hajime Ishikawa: None declared, Asami Abe: None declared, Satoshi Ito Speakers bureau: Abbvie,Eisai, Akira Murasawa: None declared, Keiichiro Nishida Grant/research support from: K. Nishida has received scholarship donation from CHUGAI PHARMACEUTICAL Co., Eisai Co., Mitsubishi Tanabe Pharma and AbbVie GK., Speakers bureau: K. Nishida has received speaking fees from CHUGAI PHARMACEUTICAL Co., Eli Lilly, Janssen Pharmaceutical K.K., Eisai Co. and AYUMI Pharmaceutical Corporation., Toshifumi Ozaki: None declared

scholarly journals Targeting miR-146a to Treat Delayed Wound Healing in Human Diabetic Organ-Cultured Corneas

PLoS ONE ◽  
2014 ◽  
Vol 9 (12) ◽  
pp. e114692 ◽  
Author(s):  
Michael A. Winkler ◽  
Christian Dib ◽  
Alexander V. Ljubimov ◽  
Mehrnoosh Saghizadeh
Keyword(s):  
Wound Healing ◽  
Delayed Wound Healing

scholarly journals Loss of endothelial-ARNT in adult mice contributes to dampened circulating proangiogenic cells and delayed wound healing

2014 ◽  
Vol 19 (6) ◽  
pp. 429-441 ◽  
Author(s):  
Yu Han ◽  
Jiayi Tao ◽  
Alla Gomer ◽  
Diana L Ramirez-Bergeron
Keyword(s):  
Wound Healing ◽  
Delayed Wound Healing ◽  
Adult Mice

scholarly journals Delayed Wound Healing and Epidermal Hyperproliferation in Mice Lacking JunB in the Skin

2006 ◽  
Vol 126 (4) ◽  
pp. 902-911 ◽  
Author(s):  
Lore Florin ◽  
Julia Knebel ◽  
Paola Zigrino ◽  
Birgitta Vonderstrass ◽  
Cornelia Mauch ◽  
...  
Keyword(s):  
Wound Healing ◽  
Delayed Wound Healing

scholarly journals Understanding the perspectives of forkhead transcription factors in delayed wound healing

2018 ◽  
Vol 13 (2) ◽  
pp. 151-162 ◽  
Author(s):  
Naresh Kumar Rajendran ◽  
Sathish Sundar Dhilip Kumar ◽  
Nicolette Nadene Houreld ◽  
Heidi Abrahamse
Keyword(s):  
Wound Healing ◽  
Transcription Factors ◽  
Delayed Wound Healing ◽  
Forkhead Transcription Factors
Sign in / Sign up

Export Citation Format

Share Document